Amphastar Pharmaceuticals

American pharmaceutical company

Amphastar Pharmaceuticals, Inc.

Company type| Public

Traded as

* Nasdaq: AMPH
* S&P 600 component

Headquarters| Rancho Cucamonga, California, United States

Key people

* Mary Z. Luo
* (Chairman of the Board)
* Jack Yongfeng Zhang
* (CEO)

Revenue|  US$ 644.4 million (2023)

Operating income

|  US$ 196.9 million (2023)

Net income

|  US$ 137.5 million (2023)
Total assets|  US$ 741.9 million (2022)
Total equity|  US$ 528.6 million (2022)

Number of employees

| 1,615
Website| Amphastar.com
Footnotes / references
[1][2][3]

Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company.[4] It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.[5]

One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic.[6] In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.[6]

In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.[7]

In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn.[8][9]

## See also

[edit]

* List of S&P 600 companies

## References

[edit]

1. ^ "U.S. SEC: Form 10-K, Amphstar Pharmaceuticals, Inc". U.S. Securities and Exchange Commission. Retrieved July 31, 2023.
2. ^ "Amphastar Pharmaceuticals Inc". Bloomberg. Retrieved 2024-03-19.
3. ^ "Amphastar Pharmaceuticals, Inc. (AMPH) Income Statement - Yahoo Finance". finance.yahoo.com. Retrieved 2024-03-19.
4. ^ "Amphastar Pharmaceuticals, Inc. (AMPH)". NASDAQ.com. NASDAQ OMX Group. Retrieved 3 January 2016.
5. ^ "Profile:Amphastar Pharmaceuticals Inc (AMPH.O)". Reuters.
6. ^ a b Arsalan, Arif (February 21, 2017). "After steering through a controversy over soaring price of naloxone, FDA rejects Amphastar's intranasal version". Endpoints.
7. ^ Raymond, Nate (June 19, 2019). "Momenta, Amphastar settle generic Lovenox drug patent case". Reuters. Retrieved March 14, 2024.
8. ^ "Eli Lilly Divests Low Blood Sugar Drug Baqsimi To Amphastar For $500M Cash". Yahoo Finance. 24 April 2023. Retrieved 2023-04-26.
9. ^ "Amphastar buys Baqsimi to build out specialty med offering". www.thepharmaletter.com. Retrieved 2023-04-26.

## External links

[edit]

* Official website
*   * Business data for Amphstar Pharmaceuticals, Inc.:

* Google
* SEC filings
* Yahoo!

This United States corporation or company article is a stub. You can help Wikipedia by expanding it.

|

* v
* t
* e

*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template